カテゴリ： GlobalData, 企業調査, 日本

Takeda Pharmaceutical Co Ltd (4502)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Takeda Pharmaceutical Co Ltd (4502) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C10103
◆発行会社（調査会社）：GlobalData
◆発行日：2018年11月
◆ページ数：398
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：日本
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Takeda Pharmaceutical Company Ltd (Takeda) is a research-based global pharmaceutical company which focuses on the research and development, manufacture, marketing, commercialization and import and export of pharmaceutical drugs and consumer health care products. The company manufactures and markets a wide range of products including photographic chemicals, inorganic chemicals, vitamin bulks, test reagents and clinical diagnostics. Takeda markets its drugs worldwide through its subsidiaries in North America, Europe and Asia. It operates production facilities in Osaka and Hikari in Japan; Italy; Ireland; Germany; Austria; Denmark; Belgium; Norway; Poland; Russia; China; Indonesia; Mexico; Brazil; Argentina; Columbia; Estonia; and India. It also operates research and development facilities at various locations in Japan and the US, China and the UK; and in Brazil, Germany, Switzerland, and Singapore. Takeda is headquartered in Chuo-ku, Osaka, Japan.

Takeda Pharmaceutical Co Ltd (4502) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 10
List of Figures 15
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19
Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deal Details 44
Asset Purchase 44
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44
Venture Financing 45
VelosBio Raises USD58 Million in Series A Financing 45
Ambys Medicines Raises USD60 Million in Series A Venture Financing 46
StrideBio Raises USD15.7 Million in Series A Financing 47
Cortexyme Raises USD76 Million in Series B Venture Financing 48
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50
Univercells Raises USD3.5 Million in Series A2 Financing 52
Hookipa Biotech Raises USD58.8 Million in Series C Financing 53
Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55
Chordia Therapeutics Raises Funds in Series A Financing 56
TiGenix Raises USD0.02 Million in Venture Financing 57
Outpost Medicine Raises Additional USD20 Million in Series A Financing 58
Palleon Pharma Raises USD47.6 Million in Series A Financing 59
OrphoMed Raises USD39 Million in Series A Financing 60
Biomx Raises USD24 Million in Series A Venture Financing 61
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63
Cerevance Raises USD21.5 Million in Series A Financing 65
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67
Cortexyme Raises USD15 Million in Series A Financing Round 69
Protekt Therapeutics Raises More Than USD2 Million in Financing 70
Univercells Raises USD3.4 Million in Equity Financing Round 71
Encycle Therapeutics Raises USD2 Million in Seed Financing 72
Presage Biosciences Raises Funds through Venture Financing 73
Naurex Raises USD80 Million in Series C Venture Financing 74
Naurex Raises US$25 Million In Venture Financing 76
VHsquared Secures Series A Funding Round 78
Hookipa Biotech Raises US$27 Million In Series B Financing 79
TiGenix Raises USD8.5 Million in Venture Financing 81
Heptares Therapeutics Raises US$21 Million In Series B Financing 82
Redwood Bioscience Raises US$8.6 Million In Venture Financing 83
Naurex Raises US$38 Million In Series B Financing 84
ArmaGen Technologies Raises US$17 Million In Series A Financing 86
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 88
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 90
Private Equity 91
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92
Partnerships 93
Molecular Templates Enters into Agreement with Takeda Pharma 93
Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94
HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95
leon-nanodrugs Enters into Agreement with Takeda Pharma 96
HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97
Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98
Takeda Pharma Enters into Agreement with DNDi 99
Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100
Fujifilm and Takeda Pharma Enter into Agreement 101
Takeda Pharma and Denali Therapeutics to Enter into Agreement 102
Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103
Takeda Pharma and Portal Instruments Enter into Agreement 104
Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105
Recursion Pharma Enters into Agreement with Takeda Pharma 106
Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107
HitGen Enters into Agreement with Takeda Pharma 108
Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110
Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111
Millennium Pharma and Shattuck Labs Enter into Research Agreement 112
Takeda Pharma Partners with Stanford University 113
Takeda Pharma Enters into Research Agreement with Molecular Templates 114
Takeda Pharma and Cardurion Pharma Enter into Partnership 115
Takeda Pharma and Schrodinger Enter into Research Partnership 116
Prana Biotech Enters into Research Agreement with Takeda Pharma 117
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118
Numerate Enters into Agreement with Takeda Pharma 119
Nektar Therapeutics Enters into Agreement with Takeda Pharma 120
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122
Takeda Pharma Enters into Agreement with NuBiyota 123
PRA Health Sciences and Takeda Pharma Form Joint Venture 124
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125
INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128
Takeda Pharma Enters into Agreement with Maverick Therapeutics 130
Takeda Pharma and Ovid Therapeutics Enter into Agreement 131
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133
Arcturus Therapeutics Extends Agreement with Takeda Pharma 134
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135
EnGeneIC Enters into Agreement with Millennium Pharma 136
Takeda Pharma Enters into Agreement with Affilogic 137
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138
PRA Health Sciences Enters into Agreement with Takeda Pharma 139
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140
TB Alliance and Takeda Pharma Enter into Agreement 141
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142
Ariad Pharma Enters into Distribution Agreement with Biologix 143
Takeda Pharma Enters into Agreement with M2Gen 144
Takeda Pharma Forms Joint Venture with Roivant Sciences 145
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147
Prosetta Biosciences Enters into Agreement with Takeda Pharma 148
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149
RaQualia Pharma Enters into Agreement with Takeda Pharma 150
TiGenix Forms Partnership with TFS International 151
Teva Pharma and Takeda Pharma Form Joint Venture 152
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154
Broad Institute Genomic Services Partners with Takeda Pharma 155
Takeda Pharma Enters into Partnership with enGene 156
Takeda Pharma Enters into Agreement with Enterome Bioscience 157
Vipergen Enters into Agreement with Takeda Pharma 158
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159
Takeda Pharma Enters into R&D Agreement with Cour Pharma 160
University College London Enters into Research Agreement with Takeda Pharma 161
Takeda Pharma Enters into Agreement with Nanotherapeutics 162
DNDi Enters into Agreement with Takeda Pharma 163
ARIAD Pharma Enters into Distribution Agreement with Paladin 164
Takeda Pharma Enters into Agreement with Sanford-Burnham 165
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168
CiRA Enters into Co-Development Agreement with Takeda Pharma 169
BioXcel Enters into Agreement with Takeda Development Center Americas 170
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176
Presage Biosciences Expands its Research Agreement with Takeda Pharma 177
GE Healthcare Enters into R&D Agreement with Takeda Pharma 178
GVK Biosciences Forms Joint Venture with Takeda Pharma 179
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185
Mersana Therapeutics Expands Agreement with Takeda Pharma 186
Mersana Expands Co-Development Agreement with Takeda Pharma 187
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188
Takeda Enters into R&D Agreement with University College London 190
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192
OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194
TiGenix To Enter Into Co-Marketing Agreement For Cx601 195
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199
Scripps Research Institute Expands Research Agreement With Takeda 200
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202
Gladstone Enters into Research Agreement with Takeda Pharma 204
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210
Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214
CIC bioGUNE Enters into Agreement with Millennium Pharma 215
Takeda Pharma Enters Into Research Agreement With Osaka University 216
Licensing Agreements 217
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217
Takeda Pharma Enters into Licensing Agreement with Enterome 218
ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219
FIMECS Enters into Licensing Agreement with Takeda Pharma 220
Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221
Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222
Mesoblast Enters into Licensing Agreement with TiGenix 224
Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228
Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229
Millennium Pharma Enters into Licensing Agreement with Tesaro 230
Takeda Pharma Enters into Licensing Agreement with Selexis 231
Biological E Enters into Licensing Agreement with Takeda Pharma 232
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233
Katairo Enters into Licensing Agreement with Takeda Pharma 234
Takeda Pharma Enters into Licensing Agreement with Exelixis 235
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241
Dermira Enters into Option Agreement with Takeda Pharma 242
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243
Incyte Amends Licensing Agreement with ARIAD Pharma 244
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246
Takeda Pharma Enters into Licensing Agreement with Gencia 247
Takeda Enters into Licensing Agreement with ImmunoGen 248
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249
Mersana Exercises Option for License Agreement with Millennium 250
Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266
Equity Offering 267
Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269
Chordia Therapeutics Spin Out from Takeda Pharma 271
Molecular Templates Raises USD20 million in Equity Financing 272
TiGenix Raises USD35.7 Million in Public Offering of ADS 273
TiGenix to Raise USD10.4 Million in Private Placement of Shares 275
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276
TiGenix Raises USD26 Million in Private Placement of Shares 278
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280
TiGenix Raises USD9.2 Million in Private Placement of Shares 281
TiGenix Completes Private Placement Of Shares For US$16.2 Million 282
TiGenix Completes Private Placement Of Shares For US$8.5 Million 283
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 284
TiGenix Completes Private Placement Of Shares For US$9 Million 286
Debt Offering 287
Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287
Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288
TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290
TiGenix Announces Private Placement Of Debt Securities For US$13.7 Million 291
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 292
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 293
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 294
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 295
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 296
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 297
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 298
Asset Transactions 299
Takeda Pharma May Sell Shire’s Ophthalmology Products 299
Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301
Acino International Acquires Manufacturing Business from Takeda Pharma 302
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 309
Acquisition 310
Takeda Pharma Acquires TiGenix for USD626.4 Million 310
Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312
Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313
Takeda Pharma to Acquire Shire 314
Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318
Takeda Acquires Altos Therapeutics 320
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324
TiGenix Acquires Coretherapix from Genetrix 326
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329
AstraZeneca May Acquire Ariad Pharma 330
Takeda America Completes Acquisition Of Inviragen For US$250 Million 332
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 334
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 336
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 338
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 339
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 341
Takeda Completes Acquisition Of Intellikine For US$310 Million 343
Takeda Pharmaceutical Co Ltd – Key Competitors 345
Takeda Pharmaceutical Co Ltd – Key Employees 346
Takeda Pharmaceutical Co Ltd – Locations And Subsidiaries 347
Head Office 347
Other Locations & Subsidiaries 347
Joint Venture 354
Recent Developments 356
Strategy And Business Planning 356
Sep 21, 2018: Takeda and Molecular Templates partner on protein-based cancer therapy 356
Aug 10, 2018: Ambys Medicines and Takeda to develop new therapies for liver diseases 357
Oct 01, 2017: ChromaJean to Launch at Takeda’s Shonan Research Center 358
Jul 31, 2017: SEEDSUPPLY to Launch at Takeda’s Shonan Research Center 359
Jul 10, 2017: Takeda Announces the Start of Operations for AXCELEAD at its Shonan Research Center 360
Jun 16, 2017: Takeda Announces Completion of New Manufacturing Facilities at the Oranienburg Site in Germany 361
May 15, 2017: Takeda Announces Establishment of its Wholly-owned Subsidiary at Shonan Research Center which Supports Drug Discovery to Drive Innovation 362
Apr 03, 2017: Takeda Consumer Healthcare Company starts its business 363
Feb 20, 2017: Takeda Announces Further Details of Splitting off (Simple Absorption-type Split) of Japan Consumer Healthcare Business Unit 364
Financial Announcements 366
Oct 31, 2018: Takeda reports second quarter FY2018 results 366
Jul 31, 2018: Takeda reports first quarter financial result 2018 results 368
May 14, 2018: Takeda reports FY2017 full year results and issues FY2018 guidance 370
Feb 01, 2018: Takeda Reports 3rd Quarter FY2017 Results 372
Nov 01, 2017: Takeda Reports First Half FY2017 Results 373
Jul 27, 2017: Takeda reports 1st Quarter FY2017 results 374
May 10, 2017: Takeda reports FY2016 full year results and issues FY2017 guidance 375
Feb 01, 2017: Takeda reports Q3 FY2016 results and improves year-end outlook 376
Corporate Communications 377
Mar 08, 2018: Takeda Announces Resignation of James Kehoe and Appointment of Costa Saroukos as CFO 377
Mar 30, 2017: Takeda Announces Ricardo Marek as New President of Emerging Markets Business Unit 378
Government and Public Interest 379
Jul 09, 2018: Takeda Announces Selection of Three New Programs for Global Corporate Social Responsibility CSR Program 2018 Promoting Disease Prevention to Improve Health in Developing and Emerging Countries 379
Jun 07, 2018: Takeda pioneers NICE’s new service for economic model review 381
Jul 27, 2017: Takeda selected by major index and sustainability rating institutions concerning Corporate Social Responsibility 382
Jun 30, 2017: Takeda Announces Selection of Global CSR Programs Emphasizing Prevention for Health in Developing and Emerging Countries 383
Feb 08, 2017: Takeda Presents $1 Million Gift to the Koch Institute for Integrative Cancer Research at MIT to Support Immuno-oncology Research 384
Product News 385
06/22/2017: NICE approves COPD treatment roflumilast for routine NHS use 385
Product Approvals 386
Sep 11, 2017: AstraZeneca’s Daxas Rejects For Use Within NHS Scotland 386
Apr 28, 2017: NICE issues ponatinib recommendation 387
Clinical Trials 388
Aug 13, 2018: Samsung Bioepis to begin Phase l trial of SB26 for pancreatitis 388
Mar 22, 2018: Takeda Announces Publication of Final Data from ICLUSIG (ponatinib) Pivotal Phase 2 PACE Trial in Blood 389
Nov 01, 2017: Data To Be Presented On ICLUSIG (ponatinib) During 59th American Society of Hematology Annual Meeting 391
Nov 01, 2017: Incyte Presents Ponatinib Data at 59th Annual ASH Meeting 392
Other Significant Developments 393
Aug 15, 2018: Crescendo Biologics reaches technical milestone for a second target in strategic collaboration with Takeda 393
Jul 02, 2018: Takeda Global Headquarters Grand Opening 394
Mar 20, 2018: Completion of Takeda Global Headquarters 395
Nov 10, 2017: Takeda Supports Launch of Five-Year, $1M Initiative Spearheaded by the Massachusetts Life Sciences Center to Back Women-Driven Early Stage Companies 396
Mar 13, 2017: INCJ, Takeda, and MEDIPAL HOLDINGS Partner to Launch a Biotech Venture 397
Appendix 398
Methodology 398
About GlobalData 398
Contact Us 398
Disclaimer 398

List of Tables
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 17
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Takeda Pharmaceutical Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 19
Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 22
Takeda Pharma Acquires Biologics Manufacturing Facility from Baxalta 44
VelosBio Raises USD58 Million in Series A Financing 45
Ambys Medicines Raises USD60 Million in Series A Venture Financing 46
StrideBio Raises USD15.7 Million in Series A Financing 47
Cortexyme Raises USD76 Million in Series B Venture Financing 48
Crescendo Biologics Raises USD69.1 Million in Series B Venture Financing 50
Univercells Raises USD3.5 Million in Series A2 Financing 52
Hookipa Biotech Raises USD58.8 Million in Series C Financing 53
Obsidian Therapeutics Raises USD49.5 Million in Series A Financing 55
Chordia Therapeutics Raises Funds in Series A Financing 56
TiGenix Raises USD0.02 Million in Venture Financing 57
Outpost Medicine Raises Additional USD20 Million in Series A Financing 58
Palleon Pharma Raises USD47.6 Million in Series A Financing 59
OrphoMed Raises USD39 Million in Series A Financing 60
Biomx Raises USD24 Million in Series A Venture Financing 61
Avidity Biosciences Raises USD10 Million in Series B Venture Financing 63
Cerevance Raises USD21.5 Million in Series A Financing 65
Bioniz Therapeutics Raises USD13 Million in Series A Venture Financing 66
Mersana Therapeutics Raises USD33 Million in Series C Financing Round 67
Cortexyme Raises USD15 Million in Series A Financing Round 69
Protekt Therapeutics Raises More Than USD2 Million in Financing 70
Univercells Raises USD3.4 Million in Equity Financing Round 71
Encycle Therapeutics Raises USD2 Million in Seed Financing 72
Presage Biosciences Raises Funds through Venture Financing 73
Naurex Raises USD80 Million in Series C Venture Financing 74
Naurex Raises US$25 Million In Venture Financing 76
VHsquared Secures Series A Funding Round 78
Hookipa Biotech Raises US$27 Million In Series B Financing 79
TiGenix Raises USD8.5 Million in Venture Financing 81
Heptares Therapeutics Raises US$21 Million In Series B Financing 82
Redwood Bioscience Raises US$8.6 Million In Venture Financing 83
Naurex Raises US$38 Million In Series B Financing 84
ArmaGen Technologies Raises US$17 Million In Series A Financing 86
Juventas Therapeutics Raises US$22.2 Million In Series B Venture Financing Round 88
LigoCyte Pharmaceuticals Raises US$2 Million In Venture Financing Round 90
Valeant Pharma Rejects Joint Takeover Bid from Takeda Pharma and TPG Capital Management 91
Sarissa Capital Acquires 6.22% Stake In Ariad Pharma 92
Molecular Templates Enters into Agreement with Takeda Pharma 93
Ambys Medicines and Takeda Pharma Enter into Partnership Agreement 94
HiFiBiO Therapeutics Enters into Agreement with Takeda Pharma 95
leon-nanodrugs Enters into Agreement with Takeda Pharma 96
HaemaLogiX Enters into Research Collaboration Agreement Takeda Pharma 97
Nektar Therapeutics Enters into Clinical Collaboration with Takeda Pharma 98
Takeda Pharma Enters into Agreement with DNDi 99
Beacon Discovery Enters into Drug Discovery Agreement with Takeda Pharma 100
Fujifilm and Takeda Pharma Enter into Agreement 101
Takeda Pharma and Denali Therapeutics to Enter into Agreement 102
Takeda Pharma and Montreal Neurological Institute and Hospital Enter into Research Partnership 103
Takeda Pharma and Portal Instruments Enter into Agreement 104
Takeda Pharma and HemoShear Therapeutics Enter into Agreement 105
Recursion Pharma Enters into Agreement with Takeda Pharma 106
Takeda Pharma, Karolinska Institutet and Structural Genomics Consortium Enter into Agreement 107
HitGen Enters into Agreement with Takeda Pharma 108
Millennium Pharma and Noile-Immune Biotech Enter into Agreement 109
AstraZeneca and Takeda Pharma Enter into Co-Development Agreement 110
Samsung Bioepis Enters into Co-Development Agreement with Takeda Pharma 111
Millennium Pharma and Shattuck Labs Enter into Research Agreement 112
Takeda Pharma Partners with Stanford University 113
Takeda Pharma Enters into Research Agreement with Molecular Templates 114
Takeda Pharma and Cardurion Pharma Enter into Partnership 115
Takeda Pharma and Schrodinger Enter into Research Partnership 116
Prana Biotech Enters into Research Agreement with Takeda Pharma 117
Heidelberg Pharma Enters into Research Agreement with Takeda Pharma 118
Numerate Enters into Agreement with Takeda Pharma 119
Nektar Therapeutics Enters into Agreement with Takeda Pharma 120
Takeda Pharma and GammaDelta Therapeutics Enter into Partnership 121
Takeda Pharma and Harrington Discovery Institute Enter into Partnership 122
Takeda Pharma Enters into Agreement with NuBiyota 123
PRA Health Sciences and Takeda Pharma Form Joint Venture 124
Center for iPS Cell Research and Application, Takeda Pharma and RIKEN Enter into Partnership 125
INCJ, Takeda Pharma and MediPal Holdings Form Joint Venture 126
Innovation Network Corporation of Japan, Takeda Pharma and MEDIPAL HOLDINGS Enter into Partnership 127
Takeda Pharma and Shionogi Enter into Research Agreement with Sumitomo Dainippon Pharma, Ono Pharma and Mitsubishi Tanabe Pharma 128
Takeda Pharma Enters into Agreement with Maverick Therapeutics 130
Takeda Pharma and Ovid Therapeutics Enter into Agreement 131
Takeda Pharma Enters into Development Agreement wtih PvP Biologics 133
Arcturus Therapeutics Extends Agreement with Takeda Pharma 134
CiRA, Takeda Pharma and Yokohama City University Enter into Research Agreement 135
EnGeneIC Enters into Agreement with Millennium Pharma 136
Takeda Pharma Enters into Agreement with Affilogic 137
Zydus Cadila Healthcare Enters into Agreement with Takeda Pharma 138
PRA Health Sciences Enters into Agreement with Takeda Pharma 139
Biomedical Advanced Research and Development Authority Enters into Agreement with Takeda Pharma 140
TB Alliance and Takeda Pharma Enter into Agreement 141
Ariad Pharma Enters into Distribution Agreement with Pint Pharma International 142
Ariad Pharma Enters into Distribution Agreement with Biologix 143
Takeda Pharma Enters into Agreement with M2Gen 144
Takeda Pharma Forms Joint Venture with Roivant Sciences 145
Takeda Pharma Enters into Co-Development Agreement with Ultragenyx Pharma 146
Astellas Pharma, Daiichi Sankyo and Takeda Pharma Enter into Research Agreement 147
Prosetta Biosciences Enters into Agreement with Takeda Pharma 148
Adimab Enters into Drug Discovery Agreement with Takeda Pharma 149
RaQualia Pharma Enters into Agreement with Takeda Pharma 150
TiGenix Forms Partnership with TFS International 151
Teva Pharma and Takeda Pharma Form Joint Venture 152
Takeda Pharma Enters into Research Agreement with University of Chicago and Icahn School of Medicine at Mount Sinai 154
Broad Institute Genomic Services Partners with Takeda Pharma 155
Takeda Pharma Enters into Partnership with enGene 156
Takeda Pharma Enters into Agreement with Enterome Bioscience 157
Vipergen Enters into Agreement with Takeda Pharma 158
Center for iPS Cell Research and Application Enters into Agreement with Takeda Pharma 159
Takeda Pharma Enters into R&D Agreement with Cour Pharma 160
University College London Enters into Research Agreement with Takeda Pharma 161
Takeda Pharma Enters into Agreement with Nanotherapeutics 162
DNDi Enters into Agreement with Takeda Pharma 163
ARIAD Pharma Enters into Distribution Agreement with Paladin 164
Takeda Pharma Enters into Agreement with Sanford-Burnham 165
National Cancer Center and Takeda Pharma to Develop Anti-Cancer Agents 166
Ariad Pharma Enters into Distribution Agreement with GEN Ilac 167
Takeda Enters into Research Agreement with Keio University School of Medicine and Niigata University 168
CiRA Enters into Co-Development Agreement with Takeda Pharma 169
BioXcel Enters into Agreement with Takeda Development Center Americas 170
Queen Mary University of London Enters into Research Agreement with Takeda Pharma 171
Prasco Lab Enters into Co-Marketing Agreement with Takeda Pharma 172
Ariad Pharma Enters into Co-Marketing Agreement with Angelini Pharma for Iclusig 173
Ariad Pharma Enters into Co-Marketing Agreement with Otsuka Pharma for Iclusig 174
Monash Institute and Monash University Enter into Research Agreement with Takeda Pharma 176
Presage Biosciences Expands its Research Agreement with Takeda Pharma 177
GE Healthcare Enters into R&D Agreement with Takeda Pharma 178
GVK Biosciences Forms Joint Venture with Takeda Pharma 179
MacroGenics Enters into Co-Development Agreement with Takeda Pharma 180
Meiji Seika Pharma Enters into Co-Promotion Agreement with Takeda Pharma for Rozerem 181
Takeda Pharma Enters Option Agreement with MacroGenics for MGD010 182
Pantec Biosolutions Enters into Research Agreement with Takeda Pharma 184
Teva Pharma Enters Into Agreement With Takeda Pharma To Commercialize Rasagiline In Japan 185
Mersana Therapeutics Expands Agreement with Takeda Pharma 186
Mersana Expands Co-Development Agreement with Takeda Pharma 187
Otsuka Enters Into Co-Promotion Agreement With Takeda For TAK-438 188
Takeda Enters into R&D Agreement with University College London 190
Ariad Pharma Enters Into Agreement With Specialised Therapeutics To Commercialize Iclusig In Australia 191
Takeda Pharma Enters Into Co-Marketing Agreement With Research Foundation For Microbial Diseases Of Osaka University 192
OrbiMed Israel Partners, JJDC and Takeda Ventures Form Joint Venture 193
Takeda Pharma Enters into Agreement with Medicines for Malaria Venture 194
TiGenix To Enter Into Co-Marketing Agreement For Cx601 195
Tri-Institutional Therapeutics Expands Agreement with Takeda Pharma 196
Takeda Nycomed Enters Into Co-Marketing Agreement With Shire For Calcichew D3 Portfolio 197
Takeda Pharma Enters Into Co-Promotion Agreement With Sanofi For Alogliptin 198
Interprotein Enters Into Agreement With Takeda Pharma For PPI Inhibitors 199
Scripps Research Institute Expands Research Agreement With Takeda 200
Takeda Pharma Enters Into Co-Development Agreement With Resolve Therapeutics 201
Sanford-Burnham And Florida Hospital Extend Research Agreement With Takeda 202
Gladstone Enters into Research Agreement with Takeda Pharma 204
Hyundai Pharma Enters into Distribution Agreement with Takeda Pharma for TachoSil 205
Takeda Pharma Enters Into Drug Discovery Agreement With Advinus Therapeutics 206
Takeda Pharma Enters Into Distribution Agreement With Johnson & Johnson For Seven OTC Brands 207
Jeil Pharma Enters Into Distribution Agreement With Takeda Pharma For Dexilant 208
Riken Enters Into Agreement With Takeda Pharma To Form Riken Bsi-Takeda Collaboration Center 209
Metabolon Enters Into Co-Development Agreement With Takeda Pharma 210
Seattle Genetics And Millennium Pharma Enter Into Co-Development Agreement With Ventana Medical Systems 211
Presage Biosciences Enters Into Co-Development Agreement With Millennium Pharma For Cancer Drugs 213
Affymax Enters Into Co-Promotion Agreement With Takeda For Peginesatide 214
CIC bioGUNE Enters into Agreement with Millennium Pharma 215
Takeda Pharma Enters Into Research Agreement With Osaka University 216
Takeda Pharma Exercises Option for Licensing Agreement with Crescendo Biologics 217
Takeda Pharma Enters into Licensing Agreement with Enterome 218
ASKA Pharma Enters into Licensing Agreement with Takeda Pharma 219
FIMECS Enters into Licensing Agreement with Takeda Pharma 220
Rhythm Pharma Enters into Licensing Agreement with Takeda Pharma 221
Takeda Pharma to Enter into Licensing Agreement with Wave Life Sciences 222
Mesoblast Enters into Licensing Agreement with TiGenix 224
Izana Bioscience Enters into Licensing Agreement with Takeda Pharma 225
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Dexilant 226
Hikma Pharma Expands Licensing Agreement with Takeda Pharma for Xefo 227
Hikma Pharma Enters into Licensing Agreement with Takeda Pharma for Vipedia and Edarbi 228
Takeda Pharma Enters into Licensing Agreement with Isogenica for llamdA 229
Millennium Pharma Enters into Licensing Agreement with Tesaro 230
Takeda Pharma Enters into Licensing Agreement with Selexis 231
Biological E Enters into Licensing Agreement with Takeda Pharma 232
Takeda Pharma Enters into Licensing Agreement with Finch Therapeutics 233
Katairo Enters into Licensing Agreement with Takeda Pharma 234
Takeda Pharma Enters into Licensing Agreement with Exelixis 235
Millennium Pharma Enters into Licensing Agreement with LegoChem Biosciences 236
Teva Pharma Enters into Licensing Agreement with Takeda for Attenukine 237
Takeda Pharma Enters into Licensing Agreement with TiGenix for Cx601 238
Teva Pharma Enters into Licensing Agreement with Takeda Pharma for Ninlaro 240
Takeda Pharma Enters into Licensing Agreement with Theravance Biopharma for TD-8954 241
Dermira Enters into Option Agreement with Takeda Pharma 242
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for Relugolix 243
Incyte Amends Licensing Agreement with ARIAD Pharma 244
Myovant Sciences Enters into Licensing Agreement with Takeda Pharma for RVT-602 245
Outpost Medicine Enters into Licensing Agreement with Takeda Pharma 246
Takeda Pharma Enters into Licensing Agreement with Gencia 247
Takeda Enters into Licensing Agreement with ImmunoGen 248
Takeda Enters into Licensing Agreement with Kaketsuken for Human Papillomavirus Vaccine 249
Mersana Exercises Option for License Agreement with Millennium 250
Sucampo Pharma Enters Into Licensing Agreement with Takeda Pharma 251
Takeda and Aska Pharma Enter into Licensing Agreement for Candesartan Aska 253
TiGenix Enters Licensing Agreement With Sobi for ChondroCelect 254
Sunesis Pharma Enters Into Licensing Agreement With Millennium Pharma 255
Takeda Pharma Enters Into Licensing Agreement With Arbor Pharma For Edarbi And Edarbyclor 256
NPS Pharma Enters Into Licensing Agreement With Takeda Pharma For Teduglutide And PTH 1-84 257
Apricus Biosciences Enters Into Licensing Agreement With Takeda Pharma For Vitaros 258
Takeda Pharma Enters into Licensing Agreement with Kaketsuken 259
Valeant Canada Enters into Licensing Agreement with Takeda Pharma for Edarbi and Edarbyclor 260
Takeda And Trianni Enter Into Licensing Agreement For Trianni Transgenic Mouse Platform 261
Takeda Pharma Enters Into Licensing Agreement With Natrogen Therapeutics For Inflammatory Bowel Disease 262
Teva Pharma Enters Into Licensing Agreement With Takeda Pharma For Glatiramer Acetate 263
Takeda California Enters Into Licensing Agreement With Sea Lane Biotech For ConCIRT Libraries and Technology 264
Daewoong Pharma Enters Into Licensing Agreement With Takeda Pharma For Instanyl 265
Takeda Expands Licensing Agreement With Genedata For Genedata Expressionist 266
Reborna Biosciences Raises USD2.3 Million in Private Placement of Shares 267
Infinity Pharma Plans to Raise USD2.5 Million in Public Offering of Shares 268
Arix Bioscience to Raise USD76.7 Million in Private Placement of Shares 269
Chordia Therapeutics Spin Out from Takeda Pharma 271
Molecular Templates Raises USD20 million in Equity Financing 272
TiGenix Raises USD35.7 Million in Public Offering of ADS 273
TiGenix to Raise USD10.4 Million in Private Placement of Shares 275
Ultragenyx Pharma Raises up to USD65 Million in Private Placement of Shares 276
TiGenix Raises USD26 Million in Private Placement of Shares 278
Aquinnah Pharma Raises USD5 Million in Private Placement of Shares 279
Prosetta Biosciences Raises USD31 Million in Series D Private Placement 280
TiGenix Raises USD9.2 Million in Private Placement of Shares 281
TiGenix Completes Private Placement Of Shares For US$16.2 Million 282
TiGenix Completes Private Placement Of Shares For US$8.5 Million 283
Ariad Pharma Completes Public Offering Of Common Stock For US$323 Million 284
TiGenix Completes Private Placement Of Shares For US$9 Million 286
Takeda Pharma to Raise up to USD20 Billion in Private Placement of Bonds 287
Takeda Pharma Raises USD500 Million in Private Placement of 2.45% Notes Due 2022 288
TiGenix Raises USD28.3 Million in Private Placement of 9% Bonds Due 2018 289
Ariad Pharma Raises USD200 Million in Private Placement of 3.625% Notes Due 2019 290
TiGenix Announces Private Placement Of Debt Securities For US$13.7 Million 291
Takeda Pharma Completes Public Offering Of Fourteenth Series Bonds Due 2019 For US$593.5 Million 292
Takeda Pharma Completes Public Offering Of Fifteenth Series Bonds Due 2020 For US$593.5 Million 293
Takeda Pharma Completes Private Placement Of Notes Due 2015 For US$1,500 Million 294
Takeda Pharma Completes Private Placement Of Notes Due 2017 For US$1,500 Million 295
Takeda Pharma Completes Public Offering Of Eleventh Series Bonds Due 2016 For US$870 Million 296
Takeda Pharma Completes Public Offering Of Twelfth Series Bonds Due 2017 For US$745 Million 297
Takeda Pharma Completes Public Offering Of Thirteenth Series Bonds Due 2018 For US$745 Million 298
Takeda Pharma May Sell Shire's Ophthalmology Products 299
Chinoin Pharma Acquires Colombian Production Unit from Takeda Pharma 300
Takeda Pharma Plans to Sell Additional Products to Teva Takeda Yakuhin for USD256.5 Million 301
Acino International Acquires Manufacturing Business from Takeda Pharma 302
AstraZeneca Acquires Core Respiratory Business from Takeda Pharmaceutical for USD575 Million 303
Fraunhofer ITEM Acquires Surfactant and CPA Program Assets from Takeda 304
PDL BioPharma Acquires Royalty Revenue of Iclusig from ARIAD Pharma for USD200 Million 305
Infinity Pharma Exercises Option to Acquire Duvelisib Royalty Rights from Takeda Pharma 307
Dr. Kade Pharma Acquires Portfolio Of OTC Products From Takeda 308
Caraco Pharma Completes Acquisition Of Non-Colcrys Business Of URL Pharma From Takeda Pharma For US$65 Million 309
Takeda Pharma Acquires TiGenix for USD626.4 Million 310
Shanghai Pharma to Acquire 26.34% Stake in Techpool Bio-Pharma from Takeda Pharma for USD143.4 Million 312
Sunrise Bright to Acquire 25% Stake in Techpool Bio-Pharma from Takeda Pharma for USD135.8 Million 313
Takeda Pharma to Acquire Shire 314
Novamed Fabricacao de Produtos Farmaceuticos Acquires Multilab Industria e Comercio de Produtos Farmaceuticos from Takeda Pharma 317
Johnson & Johnson, Novartis and Takeda Pharma May Acquire Hypermarcas 318
Takeda Acquires Altos Therapeutics 320
Takeda Pharma Acquires Ariad Pharma for up to USD5.2 Billion in Tender Offer 321
Takeda Pharma May Acquire Salix Pharma for up to USD10 Billion 323
Incyte Acquires ARIAD Pharma (Luxembourg) for USD140 Million 324
TiGenix Acquires Coretherapix from Genetrix 326
Takeda to Acquire Neutec Total from Neutec for up to USD121 Million 327
Takeda Pharma Acquires Minority Stake in BioMotiv for USD25 Million 328
PharmaCell Completes Acquisition of TiGenix, Operator of Cell Therapy Production Facility in Netherlands for USD7.8 Million 329
AstraZeneca May Acquire Ariad Pharma 330
Takeda America Completes Acquisition Of Inviragen For US$250 Million 332
Takeda Completes Acquisition Of Remaining 87.5% Stake In Envoy Therapeutics For Up To US$140 Million 334
Takeda America Completes Acquisition Of LigoCyte Pharma For US$60 Million 336
Takeda Pharma Invests US$5 Million In Advinus Therapeutics 338
Takeda Completes Acquisition Of Multilab, Brazilian Drugmaker, For Up To US$265 Million 339
Takeda America Completes Acquisition Of URL Pharma For US$800 Million 341
Takeda Completes Acquisition Of Intellikine For US$310 Million 343
Takeda Pharmaceutical Co Ltd, Key Competitors 345
Takeda Pharmaceutical Co Ltd, Key Employees 346
Takeda Pharmaceutical Co Ltd, Other Locations 347
Takeda Pharmaceutical Co Ltd, Subsidiaries 347
Takeda Pharmaceutical Co Ltd, Joint Venture 354

List of Figures
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 16
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 17
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 18
Takeda Pharmaceutical Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 19
Takeda Pharmaceutical Co Ltd, Medical Devices Deals, 2012 to YTD 2018 21

★海外企業調査レポート[Takeda Pharmaceutical Co Ltd (4502)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Chaman Lal Setia Exports Ltd：企業の戦略・SWOT・財務分析
    Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report Summary Chaman Lal Setia Exports Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Iron Mountain Incorporated：企業のM&A・事業提携・投資動向
    Iron Mountain Incorporated - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Iron Mountain Incorporated Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acqui …
  • Acobiom：企業の製品パイプライン分析2018
    Summary Acobiom is a biotechnology company that specializes in biomarker discovery and development of innovative diagnostics. The company undertakes the discovery of RNA and DNA biomarkers, which finds application in the areas of disease detection and classification, patient stratification, companio …
  • Macquarie Group Ltd：企業の戦略・SWOT・財務分析
    Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report Summary Macquarie Group Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Kresta Holdings Limited (KRS)：企業の財務・戦略的SWOT分析
    Kresta Holdings Limited (KRS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • SM Prime Holdings, Inc.：企業の戦略・SWOT・財務情報
    SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary SM Prime Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Keyera Corp (KEY)：石油・ガス：M&Aディール及び事業提携情報
    Summary Keyera Corp (Keyera) is a midstream oil and gas company. The company offers services such as processing, storage, transportation and marketing of oil and natural gas. It owns and operates raw gas gathering pipelines and processing plants, which collect and process raw natural gas, remove was …
  • CommScope Holding Company Inc (COMM)：企業の財務・戦略的SWOT分析
    CommScope Holding Company Inc (COMM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • Capricor Therapeutics Inc (CAPR)：企業の財務・戦略的SWOT分析
    Summary Capricor Therapeutics Inc (Capricor) is a biotechnology company that discovers, develops and commercializes biological therapeutics for the treatment of rare disorders. The company offers cardiac cell therapy and cenderitide products for the treatment of post myocardial infarction, advanced …
  • Kinder Morgan Inc (KMI)：石油・ガス：M&Aディール及び事業提携情報
    Summary Kinder Morgan Inc (KMI) is a midstream energy infrastructure company that owns and operates through a network of pipelines and terminals. Its pipelines transport natural gas, crude oil, gasoline, condensate, refined petroleum products and other products, and its terminals transload and store …
  • SMU S.A. (SMU)：企業の財務・戦略的SWOT分析
    SMU S.A. (SMU) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Aridis Pharmaceuticals Inc：製薬・医療：M&Aディール及び事業提携情報
    Summary Aridis Pharmaceuticals Inc (Aridis) is a biopharmaceutical companythat focusses on development of novel, differentiated therapies for infectious diseases. The company’s pipeline product uses disruptive platform technology to discover potent human monoclonal antibodies from patients.Its propr …
  • MI Bioresearch Inc-医療機器分野：企業M&A・提携分析
    Summary MI Bioresearch Inc (MI), formerly Molecular Imaging Inc is a research institute that offers pharmacology research services. The institute offers services such as oncology pharmacology, immuno oncology, in vitro services, imaging and radiation. Its oncology pharmacology include subcutaneous m …
  • Pan Orient Energy Corp. (POE)：石油・ガス：M&Aディール及び事業提携情報
    Summary Pan Orient Energy Corp (POE) is an independent upstream oil and gas company. The company has interests in onshore oil and gas assets in Thailand and Indonesia. It also has interests in Andora Energy Corporation, which holds properties in Northern Alberta. Its assets in Thailand include Conce …
  • Acuity Brands Inc (AYI)：企業の財務・戦略的SWOT分析
    Acuity Brands Inc (AYI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Iovance Biotherapeutics Inc (IOVA)：企業の財務・戦略的SWOT分析
    Iovance Biotherapeutics Inc (IOVA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • e-Therapeutics Plc (ETX)：企業の財務・戦略的SWOT分析
    e-Therapeutics Plc (ETX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Crescendo Biologics Ltd-製薬・医療分野：企業M&A・提携分析
    Summary Crescendo Biologics Ltd (Crescendo) is a biopharmaceutical company that manufactures antibody therapeutics based on a transgenic mouse platform. The company s pipeline includes humabody programs targeting oncology. It specializes in the antibody discoveries and development that include CAT, …
  • Aliaxis S.A.：企業の戦略・SWOT・財務情報
    Aliaxis S.A. - Strategy, SWOT and Corporate Finance Report Summary Aliaxis S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Ryerson Holding Corp：戦略・SWOT・企業財務分析
    Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report Summary Ryerson Holding Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆